Searched for
CAR T CELL THERAPY
Sam Neill dies at 78: Jurassic Park actor's final personal Instagram post goes viral. He honoured his father's 100-year-old keepsakeActor Sam Neill died at the age of 78 on Monday (July 13). His family confirmed his sudden death. Neill had recently been declared cancer-f...- Schedule H1 explained: Why did India tighten its prescription rules for high-alcohol medicines?Schedule H1 Explained: High-alcohol oral medicines now require a doctor's prescription under Schedule H1. This stricter classification mand...
- What is CAR T-cell therapy? The 'living drug' that helped Sam Neill become cancer freeAcclaimed actor Sam Neill, famous for his Jurassic Park role, has passed away. His family confirmed his death on Monday, July 13, in Sydney...
- Govt brings stem cell, gene therapies under central licensing frameworkIndia's drug regulations have been updated to include advanced treatments like cell, stem cell, gene therapies, and xenografts under centra...
- West Bengal's electronics factory push; Fed jitters hit TCSWest Bengal is exploring ways to expand electronics manufacturing under EMC 2.0. This and more in today's ETtech Top 5.
- Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- India should chart own path in treatment of rare diseases: ICMR chiefIndia is taking a groundbreaking step forward in the realm of rare disease care with a distinctive approach that champions local ingenuity ...
- Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatmentThis therapy targets multiple tumor-specific antigens, offering improved treatment precision for blood cancer patients, and significantly r...
- Gene therapy for blood cancer shows 73 per cent response rate in clinical trialsResearchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-inco...
- Bengaluru company launches low-cost treatment for blood cancerImmuneel Therapeutics, co-founded by Kiran Mazumdar-Shaw, has introduced Qartemi, India's second CAR-T cell therapy, to treat B-cell Non-Ho...
- Aurigene reports promising phase-1 data for its CAR-T therapy against myelomaAurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...
- CDSCO approves India's first CAR-T cell therapy against certain blood cancersIndian company ImmunoACT, backed by drug maker Laurus Labs, has received approval from the Central Drugs Standard Control Organization for ...
- Immuneel's CAR-T cell therapy reports positive in early phase-2 trials in IndiaThe early results from the IMAGINE study were based on the first 10 patients of the planned 24 patients to be enrolled.Both adult and child...
- An experimental treatment ‘cures’ leukemia. But, it leaves one crucial question unanswered about cancer treatmentCAR T Cell therapy involves genetically engineering T cells, white blood cells to fight cancer.
- Cellogen to bring next-gen cancer therapy to India"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...
- Laurus Labs acquires stake in IIT-Bombay incubated CAR-T cell therapy companyAs per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...
- Immuneel signs pact with Hospital Clínic de Barcelona to work on cancer therapyThe collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, said Immuneel in a press ...
Load More
